Literature DB >> 20010482

Viral infections in exacerbations of asthma and chronic obstructive pulmonary disease.

M Contoli1, B Marku, V Conti, S Saturni, G Caramori, A Papi.   

Abstract

Respiratory viral infections are recognized as the most frequent cause of asthma and chronic obstructive pulmonary disease (COPD) exacerbations with rhinovirus (i.e. the virus of the common cold) being the most frequent identified virus. The recent development of human experimental models of rhinovirus-induced asthma and COPD exacerbations represent innovative tools with the potential to increase our understanding in this field. Moreover this models will provide the opportunity to test, in a carefully controlled setting, novel pharmacological compounds. In this review we will provide an overview of the role of viral infections in asthma and COPD exacerbations and in particular we will summarize the inflammatory and immunological mechanisms that can pave the way to exacerbation following respiratory viral infection in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20010482

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  14 in total

Review 1.  The influence of virus infections on the course of COPD.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

2.  Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells.

Authors:  Sangbrita S Chattoraj; Shyamala Ganesan; Andrew M Jones; Jennifer M Helm; Adam T Comstock; Rowland Bright-Thomas; John J LiPuma; Marc B Hershenson; Umadevi S Sajjan
Journal:  Thorax       Date:  2011-02-02       Impact factor: 9.139

3.  Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza.

Authors:  Colleen S Kraft; Jesse T Jacob; Marti H Sears; Eileen M Burd; Angela M Caliendo; G Marshall Lyon
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

4.  Pneumocystis elicits a STAT6-dependent, strain-specific innate immune response and airway hyperresponsiveness.

Authors:  Steve D Swain; Nicole N Meissner; Dan W Siemsen; Kate McInnerney; Allen G Harmsen
Journal:  Am J Respir Cell Mol Biol       Date:  2011-09-29       Impact factor: 6.914

5.  Pseudomonas aeruginosa suppresses interferon response to rhinovirus infection in cystic fibrosis but not in normal bronchial epithelial cells.

Authors:  Sangbrita S Chattoraj; Shyamala Ganesan; Andrea Faris; Adam Comstock; Wai-Ming Lee; Umadevi S Sajjan
Journal:  Infect Immun       Date:  2011-08-08       Impact factor: 3.441

6.  Interleukin-1 receptor-associated kinase M (IRAK-M) promotes human rhinovirus infection in lung epithelial cells via the autophagic pathway.

Authors:  Qun Wu; Linda F van Dyk; Di Jiang; Azzeddine Dakhama; Liwu Li; Steven R White; Ashley Gross; Hong Wei Chu
Journal:  Virology       Date:  2013-08-30       Impact factor: 3.616

7.  Rhinovirus-induced barrier dysfunction in polarized airway epithelial cells is mediated by NADPH oxidase 1.

Authors:  Adam T Comstock; Shyamala Ganesan; Asamanja Chattoraj; Andrea N Faris; Benjamin L Margolis; Marc B Hershenson; Umadevi S Sajjan
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

8.  TLR2 Activation Limits Rhinovirus-Stimulated CXCL-10 by Attenuating IRAK-1-Dependent IL-33 Receptor Signaling in Human Bronchial Epithelial Cells.

Authors:  Shyamala Ganesan; Duc Pham; Yaxun Jing; Mohammad Farazuddin; Magdalena H Hudy; Benjamin Unger; Adam T Comstock; David Proud; Adam S Lauring; Uma S Sajjan
Journal:  J Immunol       Date:  2016-08-08       Impact factor: 5.422

9.  Complete coding sequence characterization and comparative analysis of the putative novel human rhinovirus (HRV) species C and B.

Authors:  Piyada Linsuwanon; Sunchai Payungporn; Kamol Suwannakarn; Thaweesak Chieochansin; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Virol J       Date:  2011-01-07       Impact factor: 4.099

10.  Randomised, double blind, placebo-controlled trial of echinacea supplementation in air travellers.

Authors:  E Tiralongo; R A Lea; S S Wee; M M Hanna; L R Griffiths
Journal:  Evid Based Complement Alternat Med       Date:  2011-12-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.